D-cycloserine, an established treatment modality for tuberculosis, is an N-methyl-D-aspartic acid (NMDA) receptor agonist currently being investigated for the treatment of anxiety disorders. The goal of treatment with D-cycloserine is to reduce the frequency and intensity of symptoms associated with anxiety disorders, and to improve patient functioning and quality of life.